If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
58
results.
Updated on
21/02/2026 [07:22:00]
Absstract of: WO2026039487A1
The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.
Absstract of: US20260048111A1
The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.
Absstract of: US20260048107A1
A vaccine is disclosed which comprises a pharmaceutically acceptable carrier and Gramnegative bacteria, genetically modified to express: at least one disease-associated antigen, linked to a signal sequence belonging to a type II secretion system; and the at least one disease-associated antigen linked to a signal sequence belonging to a type III secretion system. Uses thereof are also disclosed.
Absstract of: US20260048109A1
Provided herein are methods for vaccinating a subject against a Salmonella species, including typhoidal and non-typhoidal Salmonella species and serovars thereof with an Escherichia coli J5 dLOS/OMP vaccine. The vaccine is cross-reactive with the lipopolysaccharide conserved inner core region of the Salmonella species and cross-protective with the non-typhoidal Salmonella species. Vaccination reduces the likelihood of or prevents the onset of a salmonella infection. Also provided is a method of immunizing against antimicrobial resistant Salmonella species by complementing the J5 dLOS/OMP vaccine with a Salmonella species-specific vaccine.
Absstract of: WO2025021712A1
The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.
Absstract of: CN121517526A
本发明属于生物技术领域，涉及一种沙门菌靶向抗菌肽Yisi‑1及其应用。所述靶向抗菌肽Yisi‑1的氨基酸序列为丙氨酸‑异亮氨酸‑赖氨酸‑甘氨酸‑缬氨酸‑赖氨酸‑丙氨酸‑甘氨酸‑异亮氨酸‑精氨酸‑亮氨酸‑甘氨酸‑赖氨酸‑赖氨酸‑甘氨酸‑亮氨酸‑精氨酸‑丙氨酸，该靶向抗菌肽Yisi‑1的分子量为1836.3Da，等电点为12.1，带6个正电荷，两亲性高，对金黄色葡萄球菌、大肠杆菌、奇异变形杆菌、绿脓杆菌、白色念珠菌等均没有抑菌活性，仅对沙门菌具有抑菌活性，对鸡红细胞具有较低的溶血性。本发明的靶向抗菌肽Yisi‑1有望成为一种新的抗生素替代物，将在预防、诊断、治疗和鉴定沙门菌及其感染中具有良好的应用前景。
Absstract of: WO2025003117A1
The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.
Absstract of: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Absstract of: US20260041735A1
The present disclosure relates to a recombinant expression vector for secretion of interleukin-21 and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene and an interleukin-21 gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.
Absstract of: EP4692334A1
An aim of the present invention is to provide a bacteriophage having a wide host range for bacteria of the genus Salmonella. The present invention is a bacteriophage with bacteriolytic activity against bacteria of the genus Salmonella, in which the bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence.
Absstract of: EP4692335A1
An aim of the present disclosure is: (i) to provide a novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, or a bacteriolytic agent consisting of the same; (ii) to provide a bacteriophage having a wide host range for bacteria of the genus Salmonella, or a bacteriolytic agent consisting of the same; (iii) to provide a host-specific bacteriophage or an effective Salmonella bacteriolytic agent consisting of the same; or (iv) provide a bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, or a bacteriolytic agent consisting of the same. The present disclosure provides: a bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same.
Absstract of: US20260035440A1
The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.
Absstract of: WO2026030756A2
The composition and methods of treatment disclosed or contemplated herein include compositions and methods of treatment for liver-related diseases. The overall treatment strategy would involve the identification of a target protein or receptor within the liver that is responsible for ongoing liver injury. The strain of orally administered Salmonella Typhimurium that colonizes the liver would be engineered to secrete a particular protein or nanobody that would stop and/or reverse the progressive hepatic disease
Absstract of: WO2026027798A1
A yeast biomass composition is formed by culturing a strain of yeast in a substrate such as whey permeate to product a yeast broth, dewatering the broth to produce yeast biomass, and hydrolysing the yeast biomass. The yeast biomass composition finds utility as a feed additive for broiler chickens to reduce the adherence of pathogenic bacteria like Salmonella and E.coli to the gut wall of the chickens, thereby reducing intestinal stress and improving life daily weight gain in the chickens.
Absstract of: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Absstract of: US20260028377A1
The present invention relates to a gene construct characterized by encoding a fusion protein of flgM and Strep-tag through the linkage of an anti-sigma factor flgM gene and a gene encoding Strep-tag, enabling the expression of Strep-tag on the surface of an anti-cancer strain that can target tumor sites and stimulate immune activity, and to an anti-cancer adjuvant and tumor imaging agent that, when transformed by this construct, exhibits anti-cancer activity itself and can be effectively utilized in the diagnosis and treatment of tumor cells together with anti-cancer substances or contrast agents labeled with substances specifically interacting with Strep-tag.
Absstract of: US20260027165A1
The present disclosure relates to a recombinant expression vector for secretion of chlorotoxin and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising a flgM gene and a chlorotoxin gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.
Absstract of: WO2026024938A1
Methods of reducing or preventing intrauterine transmission of Salmonella Dublin in a subject, typically a cow, are provided. The methods include a first administration, and optionally second or more administrations, to a pregnant cow of an effective amount of an immunogenic composition to induce an immune response against S. Dublin in the cow. In some forms, the cow is infected with S. Dublin. In some forms, two or more cows are treated in parallel, for example, all cows that inseminated or otherwise became pregnant in parallel. Typically, the first administration, and optionally second or more administrations, are administered to the cow at a time(s) that reduces intrauterine transmission of S. Dublin infection from the cow to one or more of her calves compared to unvaccinated control cows and/or cows administered according to a different administration regimen. Exemplary methods of administration are provided.
Absstract of: GB2700365A
Method of performing SBA assay comprising: preparing media and buffer; preparing bacterial stock with a mother culture stock, media and buffer; diluting bacterial stock with buffer to obtain a diluted bacterial stock; adding test serum, complement, diluted bacterial stock, and buffer to form an assay solution; incubating assay solution, spotting it on an agar plate and incubating the plate; calculating antibody titre to determine the serum bactericidal activity. Kit or system for performing said SBA assay wherein they contain said media, buffer, bacterial stock and complement and optionally a package insert or label providing instructions to perform the SBA assay. Method for performing a serum bactericidal assay comprising preparing a bacterial stock with a mother culture stock and media, diluting the bacterial stock 1:100-1:6000 with buffer to obtain diluted bacterial stock, adding test serum, complement, diluted bacterial stock, and buffer to form an assay solution; incubating the assay solution, spotting it on an agar plate and incubating the plate; calculating antibody titre to determine the serum bactericidal activity. Figure 1
Absstract of: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Absstract of: CN120917035A
The present invention relates to protein bacteriocins (PBs) as therapeutic agents, and in particular to protein complexes comprising two or more PB molecules associated with a protein scaffold comprising a homologous immune protein domain against an effector portion of the corresponding PB. In particular, the present invention provides an antibacterial protein complex comprising: (a) a first PB molecule and a second PB molecule; and (b) an immune protein scaffold comprising a first immune protein domain and a second immune protein domain; wherein the first immune protein domain and the second immune protein domain are non-covalently bound to the first PB molecule and the second PB molecule, respectively.
Absstract of: WO2025003117A1
The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.
Absstract of: KR20260011330A
본 발명은 프로테오즈 펩톤, D-소르비톨, 페놀 레드, 뉴트럴 레드, 크리스탈 바이올렛 및 사카로스를 포함하는 살모넬라 균의 선별 또는 선택 배지 조성물에 관한 것이다.
Absstract of: US20260022888A1
The purpose of the (Fort's Gloves, Dry and Hold Pail) is to prevent moisture that causes the spread of bacteria from restrooms that is the cause of influenza, streptococcus, E coli, Hepatitis, MRSA, Salmonella, Shigella, and Norovirus. The pail is a new creation except for the authentic manuscript and cursive text. There is a distinct difference from the usual and traditional utility pails each community uses, because of the holder for the moisture elimination products that prevents contaminated water from spilling to the floor. Fecal and Trash water could potentially cause mildew growth on the gloves and the pail. The Dry & Hold container overall is a new Invention and a cleaner choice for the environment because the design prevents disease, foul odors.
Nº publicación: US20260022390A1 22/01/2026
Applicant:
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIV IAC [KR]
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
Absstract of: US20260022390A1
The present disclosure relates to a recombinant expression vector for secretion of melittin and an attenuated Salmonella strain transformed therewith, and provides an attenuated Salmonella strain transformed with a recombinant expression vector including an flgM gene and a melittin gene, an anticancer pharmaceutical composition including the attenuated Salmonella strain as an active ingredient, and a recombinant expression vector capable of improving the secretion ability of melittin.
BOPI
Electronic site
